ÌÒÉ«ÊÓÆµ

Skip to main content Skip to navigation

Press Releases

Select tags to filter on

Homepage Tags

Themes

Faculty of Arts

Faculty of SEM

Faculty of Social Sciences

Cross-Faculty Centres

University News

Events and Campaigns

Community, Campus and Regional

International

Other tags

New study into Tuberculosis membrane molecules will aid drug delivery

A new method to aid in the development of antibiotics for tuberculosis (TB) infections has been devised.


Scientists reveal why sprouts taste better as you get older… and why your grandparents were right all along

Researchers from the University of ÌÒÉ«ÊÓÆµ are sharing food for thought about the humble sprout this Christmas.

Fri 16 Dec 2022, 00:00 | Tags: School of Life Sciences 1 - Research

£1.7m containment facility will help tackle globally important diseases and prepare for future pandemics

A £1.7m laboratory building which will investigate infectious diseases has opened at the University of ÌÒÉ«ÊÓÆµ – helping to tackle some of the most globally important human diseases and prepare for pandemics of the future.


Bacteria found on common UK trees may act as a sink for air pollution, research finds.

Bacteria found on the leaves of common UK tree species may remove toxic carbon monoxide (CO) from the air, according to researchers from the University of ÌÒÉ«ÊÓÆµ.

Wed 25 May 2022, 12:11 | Tags: School of Life Sciences

Compounds made from ‘digested’ molecules feeds appetite for greener pharmaceuticals and agrochemicals

A method of producing vital chemical building blocks for use in the pharmaceutical and agrochemical industries that mimics how plants manufacture them has been developed by University of ÌÒÉ«ÊÓÆµ scientists.

Tue 01 Feb 2022, 12:49 | Tags: School of Life Sciences 1 - Research

Poolbeg Pharma licences first-in-class broad spectrum RNA-based immunotherapy for respiratory virus infections from the University of ÌÒÉ«ÊÓÆµ

(AIM: POLB, 'Poolbeg' or the 'Company'), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has in-licenced a novel, first-in-class RNA-based immunotherapy for respiratory virus infections developed at the University of ÌÒÉ«ÊÓÆµ.


Latest news Newer news Older news

Let us know you agree to cookies